# US 2026/0256926 A1 · Bifacial peptide nucleic acid probes and methods of using thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0256926 A1
- Document ID: US20260256926A1
- Status: Published application
- Kind: A1
- Application number: 18/992,112
- Filed: 2023-07-10
- Published: 2026-09-03
- Earliest claimed: 2022-07-08
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Dennis BONG; Shiqin MIAO; Yufeng LIANG
- Web page: https://patentgrep.com/patent/US20260256926A1

## CPC

- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- C07D 239/48: Two nitrogen atoms
- C07D 239/54: as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D 251/52: with an oxygen or sulfur atom attached to the third ring carbon atom
- C07D 251/70: Other substituted melamines
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 417/08: linked by a carbon chain containing alicyclic rings
- C07D 473/34: attached in position 6, e.g. adenine
- C12Q 1/6825: Nucleic acid detection involving sensors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein are bifacial peptide nucleic acid probes. These probes can include a triplex hybrid forming moiety (e.g., a plurality of binding motifs disposed along a peptidyl backbone) conjugated to a prosthetic group. The triplex hybrid forming moiety can bind to a non-canonical base pairing site in a target nucleic acid via triplex hybridization. In this way, a variety of prosthetic groups (e.g., dyes, labels, reactive groups, etc.) can be selectively delivered to a target nucleic acid (e.g., in vivo, in vitro, or ex vivo).

## Claims

### Claim 1

A compound defined by Formula I below
wherein
A represents a prosthetic group;
X is absent or represents a first bivalent linking group;
L is absent or represents a second bivalent linking group;
n is, individually for each occurrence, an integer selected from 1 and 2;
m is an integer selected from 2, 3, and 4;
Z represents, individually for each occurrence, a binding motif selected from one of the following
Q1 and Q2 individually represent —O— or —NRA—;
Y is N, —CRB—,
R1 is, individually for each occurrence, selected from one of the following
R2 represents, individually for each occurrence, H, a C1-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, or a C1-C4 haloalkyl group;
RA represents, individually for each occurrence, H, a C1-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, or a C1-C4 haloalkyl group; and
RB represents, individually for each occurrence, H, halogen, methyl, or trifluoromethyl.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, wherein R2 represents H for each occurrence.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein Q1 and Q2 represent —NH— for each occurrence.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is, individually for each occurrence, selected from one of the following

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1 is, individually for each occurrence, —H or —CH3.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The compound of claim 1, wherein X represents a first bivalent linking group and L represents a second bivalent linking group.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The compound of claim 1, wherein in at least one occurrence, Z represents the binding motif shown below
wherein
Q1 and Q2 individually represent —O— or —NRA—;
Y is N, —CRB—,
R2 represents, individually for each occurrence, H, a C1-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, or a C1-C4 haloalkyl group;
RA represents, individually for each occurrence, H, a C1-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, or a C1-C4 haloalkyl group; and
RB represents, individually for each occurrence, H, halogen, methyl, or trifluoromethyl.

### Claim 19 (depends on 1)

The compound of claim 1, wherein m is 3 and Z represents the binding motif shown below in two occurrences
wherein
Q1 and Q2 individually represent —O— or —NRA—;
Y is N, —CRB—,
R2 represents, individually for each occurrence, H, a C1-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, or a C1-C4 haloalkyl group;
RA represents, individually for each occurrence, H, a C1-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, or a C1-C4 haloalkyl group; and
RB represents, individually for each occurrence, H, halogen, methyl, or trifluoromethyl.

### Claim 20 (depends on 1)

The compound of claim 1, wherein the compound is defined by Formula IA below
wherein A, L, Y, Q1, Q2, X, n, and m are as defined above

### Claim 21 (depends on 1)

The compound of claim 1, wherein the compound is defined by Formula IA
wherein
A, L, R1, m, and n are as defined above; and
a is, individually for each occurrence, an integer selected from 3, 4, 5, and 6.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The compound of claim 1, wherein the prosthetic group is selected from the group consisting of a fluorogenic dye, a protein ligand, a redox-active center, an ROS-generating center, a photoreactive center, a spin label, a group transfer agent, a therapeutic agent, a catalytic center, a click motif, or an NMR active label.

### Claim 24 (depends on 23)

The compound of claim 23, wherein the prosthetic group is a fluorogenic dye selected from the group consisting of thiazole derived dyes such as thiazole orange, dimethylindole red and derivatives thereof, symmetric cyanine dyes, asymmetric cyanine dyes, fluoresceins, rhodamines, fluorogenic variants of asymmetric cyanine dyes and fluoresceins such as JF635 and JF646, arsenate dyes such as FIASH and ReASH, malachite green and derivatives thereof, coumarin dyes, and hydroxybenzylidene dyes.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 23)

The compound of claim 23, wherein the prosthetic group is a protein ligand selected from the group consisting of a ubiquitin ligase ligand, a ligand for a translational activator, a ligand for a translational inhibitor, a ligand for a transcription activator, a ligand for a transcription inhibitor, a ligand for a nuclease, or a ligand for a cell surface protein.

### Claim 28

(canceled)

### Claim 29 (depends on 27)

The compound of claim 27, wherein the protein ligand is a ubiquitin ligase ligand that binds to an E3 ligase selected from the group consisting of XIAP, VHL, cereblon, and MDM2.

### Claim 30 (depends on 1)

The compound of claim 1, wherein the compound binds to a non-canonical base pairing site in a nucleic acid via triplex hybridization.

### Claim 31

(canceled)

### Claim 32 (depends on 30)

The compound of claim 30, wherein the non-canonical base pairing site comprises a U-rich internal loop (URIL).

### Claim 33 (depends on 32)

The compound of claim 32, wherein the URIL is a loop that includes at least four non-canonical base pairs, wherein at least 50% of the non-canonical base pairs comprise U—U pairs.

### Claim 34 (depends on 33)

The compound of claim 33, wherein the URIL comprises from 4-8 non-canonical base pairs.

### Claim 35

A method of detecting a target nucleic acid comprising
contacting the target nucleic acid with a bifacial peptide nucleic acid probe comprising a triplex hybrid forming moiety conjugated to a fluorogenic dye, wherein the bifacial peptide nucleic acid probe binds to a non-canonical base pairing site in the target nucleic acid via triplex hybridization.

### Claim 36

(canceled)

### Claim 37

A method of selectively degrading a target protein in vivo, the method comprising
contacting a nucleic acid with a bifacial peptide nucleic acid probe comprising a triplex hybrid forming moiety conjugated to a ubiquitin ligase ligand,
wherein the bifacial peptide nucleic acid probe binds to a non-canonical base pairing site in the target nucleic acid via triplex hybridization;
wherein the nucleic acid forms a ribonucleoprotein complex with the nucleic acid; and
wherein the ubiquitin ligase ligand of the bifacial peptide nucleic acid probe bound to the nucleic acid directs ubiquitination of the target protein, thereby directing proteolysis of the target protein.

### Claim 38

(canceled)

### Claim 39

A method of selectively labeling a target protein in vivo, the method comprising
contacting a nucleic acid with a bifacial peptide nucleic acid probe comprising a triplex hybrid forming moiety conjugated to a redox-active center, an ROS-generating center, a photoreactive center, or a catalytic center,
wherein the bifacial peptide nucleic acid probe binds to a non-canonical base pairing site in the target nucleic acid via triplex hybridization;
wherein the nucleic acid forms a ribonucleoprotein complex with the target protein; and
wherein the redox-active center, the ROS-generating center, the photoreactive center, or the catalytic center of the bifacial peptide nucleic acid probe bound to the nucleic acid participates in a chemical reaction that results in covalent modification of the target protein, thereby labeling the target protein.

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)
